Norovirus Infection - Pipeline Insight, 2024

Norovirus Infection - Pipeline Insight, 2024

DelveInsight’s, “Norovirus Infection - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Norovirus Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Norovirus Infection: Understanding

Norovirus Infection: Overview

Norovirus Infection typically causes acute gastroenteritis. It is also a common cause of food poisoning and is usually related to consumption of undercooked shellfish. People can get Norovirus Infection from having direct contact with an infected person, consuming contaminated food or water, or by touching contaminated surfaces. Norovirus can also cause outbreaks of acute gastroenteritis in settings where people are staying close together such as schools, elderly homes, hotels, play facilities and cruise ships. The disease affects people of all age groups and tends to be more common during winter. The virus is previously known as ‘Norwalk-like viruses’.

The signs and symptoms of norovirus infection may start suddenly and include nausea, vomiting, stomach pain or cramps, watery or loose diarrhea, feeling ill, low-grade fever and muscle pain. Signs and symptoms usually begin 12 to 48 hours after the first exposure to a norovirus and last 1 to 3 days. Some people with norovirus infection may show no signs or symptoms. However, they're still contagious and can spread the virus to others. Noroviruses are highly contagious. That means the norovirus infection can easily spread to others. The infection can be caused by eating contaminated food, drinking contaminated water and by touching hand to mouth after the hand has been in contact with a contaminated surface or object and being in close contact with a person who has norovirus infection. Noroviruses are difficult to kill because they can withstand hot and cold temperatures and many disinfectants.

Norovirus infection is usually diagnosed based on the symptoms, but noroviruses can be identified from a stool sample. If the patient have a weakened immune system or have other medical conditions, the health care provider might recommend a stool test to confirm the presence of norovirus. There's no specific treatment for norovirus infection. Recovery generally depends on the health of immune system. In most people, the illness usually resolves within a few days. It's important to replace lost fluids. Oral rehydration solutions may be used. If the patient is not able to drink enough fluids to prevent dehydration, might need to receive fluids through a vein (intravenous).

There are many types of noroviruses. Anyone can get norovirus infection more than once. To prevent norovirus infection: wash your hands thoroughly with soap and water for at least 20 seconds, avoid contaminated food and water, wash fruits and vegetables before eating, Cook seafood thoroughly and avoid contact with others as much as possible.

""Norovirus Infection - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Norovirus Infection pipeline landscape is provided which includes the disease overview and Norovirus Infection treatment guidelines. The assessment part of the report embraces, in depth Norovirus Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Norovirus Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Norovirus Infection R&D. The therapies under development are focused on novel approaches to treat/improve Norovirus Infection.

Norovirus Infection Emerging Drugs Chapters

This segment of the Norovirus Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Norovirus Infection Emerging Drugs

• VXA-G1.1-NN: Vaxart

Vaxart is developing a bivalent tablet vaccine for norovirus, a leading cause of acute viral gastroenteritis and food-borne disease in the U.S. and Europe. Vaxart has completed two Phase 1 clinical trials with its monovalent oral tablet vaccine based on the GI.1 norovirus strain, demonstrating its norovirus tablet vaccine was well tolerated and generated broad systemic and mucosal immune responses. In the recently completed clinical Phase 1b dose-optimization study in healthy adults, in which Vaxart evaluated four different dosing regimens, all vaccine recipients (100%) in the high-dose group responded as measured by a significant increase in norovirus specific B cells of both IgA and IgG subtypes. In the same group, there was at least a two-fold increase of norovirus specific antibody titers in serum in more than 90% of recipients 56 days after dosing. Currently, the drug is in Phase II stage of its development for the treatment of norovirus infection.

• CDI 988: Cocrystal Pharma Inc

CDI-988 is a pan-viral protease inhibitor that was discovered using the Company’s proprietary structure-based drug discovery platform technology. The drug candidate is an oral antiviral candidate has the potential to save patient lives and reduce the severity of norovirus and coronavirus infections. Recent CDI-988 in vitro studies showed potent broad-spectrum antiviral activity against a panel of pandemic GII.4 norovirus proteases and a favorable pharmacokinetic property targeting the gastrointestinal tract. Currently, the drug is in Phase I stage of its development for the treatment of Norovirus Infection.

Further product details are provided in the report……..

Norovirus Infection: Therapeutic Assessment

This segment of the report provides insights about the different Norovirus Infection drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Norovirus Infection
• There are approx. 8+ key companies which are developing the therapies for Norovirus Infection. The companies which have their Norovirus Infection drug candidates in the most advanced stage, i.e. phase III include, Vaxart.
• Phases

DelveInsight’s report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Norovirus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Norovirus Infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Norovirus Infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Norovirus Infection drugs.

Norovirus Infection Report Insights

• Norovirus Infection Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Norovirus Infection Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Norovirus Infection drugs?
• How many Norovirus Infection drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Norovirus Infection?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Norovirus Infection therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Norovirus Infection and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Vaxart
• Cocrystal Pharma Inc
• Prosit Sole Biotechnology
• HilleVax
• iosBio
• OstriGen

Key Products

• VXA-G1.1-NN
• CDI 988
• PSP 001
• HIL 214
• Norovirus vaccine
• Research programme: antibodies